Adams “edible film” OTCs
This article was originally published in The Tan Sheet
Executive Summary
Adams Respiratory Therapeutics will develop oral thin-film drug delivery OTC and pharmaceutical respiratory products under a licensing agreement with drug delivery firm MonoSol Rx, the company announces March 27. Under the deal, Adams receives an exclusive, royalty-bearing non-transferable license from MonoSol to develop and market two or more respiratory products in North America. Under a separate agreement, MonoSol will manufacture and supply the finished products. MonoSol will complete product development, while Adams will perform all clinical development, regulatory submissions and commercial operations. Financial terms of the deal were not disclosed, but Adams notes MonoSol will receive payments in exchange for completing pre-defined development milestones. Leiner launched several OTC drug and dietary supplement products in orally dissolving strips in 2005 under a deal with MonoSol (1"The Tan Sheet" Aug. 15, 2005, p. 8)...
You may also be interested in...
Leiner, MonoSol Deal Brings Oral Strip Technology To Private Label Market
Leiner will launch at least three new OTC drug and dietary supplement products in orally dissolving strip formulations later this year under a licensing agreement with MonoSol Rx
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.